NYSE: NVONovo Nordisk A S Stock
$66.45+1.29 (+1.98%)
Updated Apr 30, 2025
NVO Price
$66.45
Fair Value Price
N/A
Market Cap
$296.70B
52 Week Low
$57.00
52 Week High
$148.15
P/E
20.99x
P/B
14.81x
P/S
9.58x
PEG
1.07x
Dividend Yield
2.43%
Revenue
$40.56B
Earnings
$14.08B
Gross Margin
84.7%
Operating Margin
43.8%
Profit Margin
34.8%
Debt to Equity
2.25
Operating Cash Flow
$17B
Beta
0.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NVO Overview
Novo Nordisk A/S manufactures pharmaceutical products and is best known as the producer of the weight loss drug Ozempic. Its Diabetes and Obesity Care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. Novo Nordisk was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NVO's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NVO
Ranked#21 of 462
Ranked#21 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important NVO news, forecast changes, insider trades & much more!
NVO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NVO scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVO ($66.45) is trading above its intrinsic value of $40.14, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVO is good value based on its earnings relative to its share price (20.99x), compared to the US market average (29.18x)
P/E vs Market Valuation
NVO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more NVO due diligence checks available for Premium users.
Valuation
NVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
20.99x
Industry
-162.28x
Market
29.18x
NVO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NVO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
NVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
14.81x
Industry
4.45x
NVO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NVO price to earnings growth (PEG)
For valuing profitable companies with growth potential
NVO is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
NVO's financial health
Profit margin
Revenue
$12.0B
Net Income
$3.9B
Profit Margin
32.9%
NVO's Earnings (EBIT) of $17.76B... subscribe to Premium to read more.
Interest Coverage Financials
NVO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$65.0B
Liabilities
$45.0B
Debt to equity
2.25
NVO's short-term liabilities ($30.38B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVO's short-term assets ($22.47B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.0B
Investing
-$13.9B
Financing
$8.6B
NVO's operating cash flow ($16.89B)... subscribe to Premium to read more.
Debt Coverage Financials
NVO vs Biotech Stocks
Novo Nordisk (Ozempic) Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.